Epratuzumab in non-Hodgkin's lymphomas.
Epratuzumab in non-Hodgkin's lymphomas.
复制标题
DOI：
10.1007/s11864-004-0019-1
复制
发表时间：
2004-08-01
影响因子：
4.3
通讯作者：
Leonard, John P
中科院分区：
文献类型：
--
作者：
Furman, Richard R;Coleman, Morton;Leonard, John P
非霍奇金淋巴瘤（NHL）是一组不同的恶性肿瘤，除了治疗外，还导致人群中显著的发病率和死亡率。确定更有效和耐受性更好的治疗方法至关重要。使用针对CD20蛋白的单克隆抗体的免疫治疗对B细胞NHL患者的管理产生了深远的影响。正在积极研究其他抗原靶点。与化疗相比，用单克隆抗体靶向淋巴瘤细胞提供了一种具有潜在的非交叉耐药作用机制和更有利的毒性特征的治疗。依帕珠单抗（人源化LL2）是一种针对CD 22蛋白的人源化免疫球蛋白G1单克隆抗体，其表达仅限于成熟B细胞。由于CD22与CD20的特征存在重要差异，依帕珠单抗可能成为NHL未来治疗的重要组成部分。
Non-Hodgkin's lymphomas (NHL) are a diverse group of malignancies that result, in addition to their treatments, in significant morbidity and mortality in the population. The identification of more effective and better tolerated treatments is of vital importance. Immunotherapy using monoclonal antibodies directed against the CD20 protein has had a profound impact on the management of patients with B-cell NHL. Additional antigen targets are being aggressively investigated. The targeting of lymphoma cells with monoclonal antibodies offers a treatment with a potentially noncross-resistant mechanism of action and a more favorable toxicity profile compared to chemotherapy. Epratuzumab (humanized LL2) is a humanized immunoglobulin G1 monoclonal antibody directed against the CD22 protein in which expression is restricted to mature B cells. Because of important differences in the characteristics of CD22 compared to CD20, epratuzumab may become an important component of future therapies for NHL.